Fig 1: Association between the expression of CLDNs and patient survival. Kaplan-Meier analysis was performed to determine the survival of patients with laryngeal squamous carcinoma. Survival was investigated according to (A) CLDN1 (P=0.004), (B) CLDN3 (P=0.014), (C) CLDN7 (P=0.012) and (D) CLDN8 expression (P=0.006). CLDN, claudin.
Fig 2: Immunohistochemical analysis of CLDN expression in human laryngeal squamous carcinoma and adjacent non-neoplastic tissues. High expression of CLDN1 in (A) non-neoplastic tissue compared with (B) laryngeal squamous carcinoma tissue. Low expression of CLDN3 in (C) non-neoplastic tissue compared with (D) laryngeal squamous carcinoma tissue. High expression of CLDN7 in (E) non-neoplastic tissue compared with (F) laryngeal squamous carcinoma tissue. Low expression of CLDN8 in (G) non-neoplastic tissue compared with (H) laryngeal squamous carcinoma tissue. Magnification, ×400. CLDN, claudin.
Fig 3: Immunohistochemistry of marker genes of cellular origin in RCCs arising in ESRD. Representative immunohistochemical findings of 2 proximal tubule cell markers (HNF1a, and HNF4a) and one distal tubule cell/collecting duct cell marker (CLDN8). ESRD-ccRCC (ESRD-ccRCC7) and ACD-associated RCC (ACD-RCC2), along with sporadic ccRCC (sporadic ccRCC5) and PRCC (PRCC8), had high expression of HNF1a and HNF4a and lacked CLDN8 expression. In contrast, ChRCC (ChRCC3) had high CLDN8 expression and lacked expression of HNF1a and HNF4a. Noncancerous, noncancerous6. Scale bars indicates 50 µm
Fig 4: Analysis of gene expression of marker genes of cellular origin in RCCs arising in ESRD. A, Expression levels of 3 proximal tubule cell markers (HNF1a, HNF4a, SLC17A3). These were highly expressed in ESRD-ccRCCs, ACD-RCCs, sporadic ccRCCs, and PRCCs. B, Expression levels of 2 distal tubule cell/collecting duct cell markers (CLDN8, SLC4A1). These were highly expressed in ChRCCs. *P < .05
Supplier Page from Abcam for Anti-Claudin 8 antibody [EPR12680(2)]